
Jacquie Maignel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3598734/publications.pdf Version: 2024-02-01



LACOLUE MAICNEL

#	Article	IF	CITATIONS
1	BoNT/A in the Urinary Bladder—More to the Story than Silencing of Cholinergic Nerves. Toxins, 2022, 14, 53.	3.4	5
2	BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study. Toxins, 2022, 14, 77.	3.4	0
3	The Isolated Mouse Jejunal Afferent Nerve Assay as a Tool to Assess the Effect of Botulinum Neurotoxins in Visceral Nociception. Toxins, 2022, 14, 205.	3.4	2
4	New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency. Toxins, 2021, 13, 834.	3.4	3
5	Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models. Science Advances, 2019, 5, eaau7196.	10.3	29
6	Exploring the effect of various BoNT serotypes in a model of autonomic nervous system hyperactivity from rodents and humans: Paving the way to better targeting therapeutics in autonomic disorders?. Toxicon, 2018, 156, S72.	1.6	1
7	The Expanding Therapeutic Utility of Botulinum Neurotoxins. Toxins, 2018, 10, 208.	3.4	79
8	Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems. PLoS ONE, 2017, 12, e0185628.	2.5	10
9	Synthesis, Structureâ^'Activity Relationships, and Pharmacological Profile of 9-Amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1- <i>hi</i>)indoles:  Discovery of Potent, Selective Phosphodiesterase Type 4 Inhibitors. Journal of Medicinal Chemistry, 2000, 43,	6.4	46